Registry-listed formulations

gusacitinib · mesh:C000707471

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    0(0%)

    Phase Distribution

    Phase 1
    1
    100%

    Phase Distribution

    1

    Early Stage

    0

    Mid Stage

    0

    Late Stage

    Phase Distribution1 total trials
    Phase 1Safety & dosage
    1(100.0%)

    Highest Phase Reached

    Phase 1

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 1 finished

    Non-Completion Rate

    100.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    1

    all time

    Status Distribution
    Terminated(1)

    Detailed Status

    Withdrawn1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    1
    Active
    0
    Success Rate
    N/A
    Most Advanced
    Phase 1

    Trials by Phase

    Phase 11 (100.0%)

    Trials by Status

    withdrawn1100%

    Recent Activity

    0 active trials
    Showing 1 of 1
    withdrawnphase_1

    A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus

    NCT06238531

    Clinical Trials (1)

    Showing 1 of 1 trials
    NCT06238531Phase 1

    A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus

    Withdrawn

    All 1 trials loaded

    Drug Details

    Intervention Type
    Drug
    Molecule Type
    Small molecule
    Total Trials
    1

    External References

    ChEMBL
    CHEMBL4594275

    Names & Codes

    Research Codes

    ASN-002EN-3351